TY - JOUR
T1 - Dipeptidyl-peptidase-IV by cleaving neuropeptide y induces lipid accumulation and PPAR-γ expression
AU - Rosmaninho-Salgado, Joana
AU - Marques, Ana Patricia
AU - Estrada, Marta
AU - Santana, Magda
AU - Cortez, Vera
AU - Grouzmann, Eric
AU - Cavadas, Cláudia
N1 - Funding Information:
This work was supported by Foundation for Science and Technology (FCT) , COMPETE , FEDER, Portugal ( PTDC/SAU-FCF/102415/2008 , SFRH/BPD/31547/2006 and SFRH/BD/44664/2008 ), by a Project Grant for Obesity investigation provided from the Portuguese Society of Endocrinology and Metabolism (SPEDM), Abbot, and by L’Oreal Women for Science Program (FCT/UNESCO-Portugal).
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/9
Y1 - 2012/9
N2 - We evaluated the effects of dipeptidyl peptidase-IV (DPPIV), and its inhibitor, vildagliptin, on adipogenesis and lipolysis in a pre-adipocyte murine cell line (3T3-L1). The exogenous rDPPIV increased lipid accumulation and PPAR-γ expression, whereas an inhibitor of DPPIV, the anti-diabetic drug vildagliptin, suppresses the stimulatory role of DPPIV on adipogenesis and lipid accumulation, but had no effect on lipolysis. NPY immunoneutralization or NPY Y2 receptor blockage inhibited DPPIV stimulatory effects on lipid accumulation, collectively, indicating that DPPIV has an adipogenic effect through NPY cleavage and subsequent NPY Y2 activation. Vildagliptin inhibits PPAR-γ expression and lipid accumulation without changing lipolysis, suggesting that this does not impair the ability of adipose tissue to store triglycerides inside lipid droplets. These data indicate that DPPIV and NPY interact on lipid metabolism to promote adipose tissue depot.
AB - We evaluated the effects of dipeptidyl peptidase-IV (DPPIV), and its inhibitor, vildagliptin, on adipogenesis and lipolysis in a pre-adipocyte murine cell line (3T3-L1). The exogenous rDPPIV increased lipid accumulation and PPAR-γ expression, whereas an inhibitor of DPPIV, the anti-diabetic drug vildagliptin, suppresses the stimulatory role of DPPIV on adipogenesis and lipid accumulation, but had no effect on lipolysis. NPY immunoneutralization or NPY Y2 receptor blockage inhibited DPPIV stimulatory effects on lipid accumulation, collectively, indicating that DPPIV has an adipogenic effect through NPY cleavage and subsequent NPY Y2 activation. Vildagliptin inhibits PPAR-γ expression and lipid accumulation without changing lipolysis, suggesting that this does not impair the ability of adipose tissue to store triglycerides inside lipid droplets. These data indicate that DPPIV and NPY interact on lipid metabolism to promote adipose tissue depot.
KW - Dipeptidyl-peptidase IV (DPPIV)
KW - Lipid accumulation
KW - Neuropeptide Y
KW - Pre-adipocyte murine cell line (3T3-L1)
UR - http://www.scopus.com/inward/record.url?scp=84865246554&partnerID=8YFLogxK
U2 - 10.1016/j.peptides.2012.06.014
DO - 10.1016/j.peptides.2012.06.014
M3 - Article
C2 - 22819773
AN - SCOPUS:84865246554
SN - 0196-9781
VL - 37
SP - 49
EP - 54
JO - Peptides
JF - Peptides
IS - 1
ER -